#longevity-market

#longevity-market

"For the ones who are confined in certain spaces or cannot do it independently, this is a great opportunity to transport them to a different reality from the ones that they are currently living in while keeping them active," Munoz told CBC Hamilton from his lab on Laurier's Brantford campus.

You just have to immerse yourself in it. You should just constantly be building. That's what's going to give you the best chance of having the relevant skill set that is needed to make a difference in technology.

Approximately 10 out of the 100 employees under his leadership had reportedly sought extended leaves of absence for mental health concerns since 2022.

Google's new health tracker, teased by Steph Curry, features a Whoop-inspired design and will include a subscription service with an AI-based personal health coach.

"Asia has more diabetes, cancer and cardiovascular patients than anywhere else in the world," Abrar Mir states, emphasizing the severity of the health crisis in the region.

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, confirming its commitment to advancing healthcare and life sciences.

These findings reposition the thymus as a central regulator of immune‑ mediated aging and disease susceptibility in adulthood.

In recent weeks, China approved the world's first commercial brain-computer interface medical device and unveiled a five-ton class electric vertical takeoff and landing aircraft that has already completed a public flight.

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

Researchers administered one of four doses of stem cells to 118 people between 70 and 85 years old, all of whom had frailty. In a timed walking test nine months after treatment, those who had received the highest dose could walk about 60 metres farther, on average, than they could before treatment.